ATE491723T1 - Neue verbindungen mit gemischter amylin aktivität - Google Patents

Neue verbindungen mit gemischter amylin aktivität

Info

Publication number
ATE491723T1
ATE491723T1 AT99906782T AT99906782T ATE491723T1 AT E491723 T1 ATE491723 T1 AT E491723T1 AT 99906782 T AT99906782 T AT 99906782T AT 99906782 T AT99906782 T AT 99906782T AT E491723 T1 ATE491723 T1 AT E491723T1
Authority
AT
Austria
Prior art keywords
treating
diabetes
amylin
compounds
type
Prior art date
Application number
AT99906782T
Other languages
English (en)
Inventor
Nigel Beeley
Kathryn Prickett
Kevin Beaumont
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE491723T1 publication Critical patent/ATE491723T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99906782T 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität ATE491723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7474698P 1998-02-13 1998-02-13
PCT/US1999/002603 WO1999040928A1 (en) 1998-02-13 1999-02-05 Novel mixed amylin activity compounds

Publications (1)

Publication Number Publication Date
ATE491723T1 true ATE491723T1 (de) 2011-01-15

Family

ID=22121450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906782T ATE491723T1 (de) 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität

Country Status (8)

Country Link
EP (1) EP1053001B1 (de)
JP (1) JP4372345B2 (de)
AT (1) ATE491723T1 (de)
AU (1) AU766653B2 (de)
CA (1) CA2320962C (de)
DE (1) DE69943039D1 (de)
ES (1) ES2356595T3 (de)
WO (1) WO1999040928A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517050A (ja) * 2000-09-19 2004-06-10 ユニバーシティ オブ トロント Ｉａｐｐ原線維形成の抑制剤およびそれらの使用
JP2004515533A (ja) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
JP2005523418A (ja) * 2001-11-26 2005-08-04 プロテミックス コーポレイション リミティド 哺乳動物組織で脂質レベルを正常化するための方法及び組成物
EP1663289A2 (de) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Verfahren zur behandlung oder linderung von erkrankungen und störungen im zusammenhang mit ghrelin
NZ549332A (en) 2004-02-11 2008-11-28 Amylin Pharmaceuticals Inc Amylin family peptides and methods for making and using them
EP2718314A2 (de) * 2011-06-10 2014-04-16 Novo Nordisk A/S Polypeptide
CN104395338B (zh) * 2012-04-19 2019-05-10 诺和诺德股份有限公司 人胰岛淀粉样多肽类似物
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT44794A (en) 1985-12-04 1988-04-28 Sandoz Ag Process for production of calcitonine-derivatives and medical preparatives containing such compounds
DE3640042A1 (de) 1985-12-04 1987-06-11 Sandoz Ag Neue calcitoninderivate
HU906341D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
DK163689A (da) * 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
EP0615522B1 (de) 1991-11-19 1999-09-22 Peptech (Uk) Limited Muramylverbindungen zur behandlung von septischem schock
EP0582693A1 (de) 1992-01-14 1994-02-16 Amylin Pharmaceuticals, Inc. Myotonin-rezeptoren und siebtesverfahren
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5625032A (en) 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
BR9407424A (pt) * 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal

Also Published As

Publication number Publication date
AU766653B2 (en) 2003-10-23
CA2320962A1 (en) 1999-08-19
EP1053001A1 (de) 2000-11-22
JP4372345B2 (ja) 2009-11-25
DE69943039D1 (de) 2011-01-27
JP2002522355A (ja) 2002-07-23
EP1053001A4 (de) 2006-01-04
AU2661299A (en) 1999-08-30
WO1999040928A1 (en) 1999-08-19
CA2320962C (en) 2011-04-19
ES2356595T3 (es) 2011-04-11
EP1053001B1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE354590T1 (de) Neue antidiabetische peptide
Urva et al. The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
DE69943039D1 (de) Neue verbindungen mit gemischter amylin aktivität
FI952536A (fi) Glukagonia muistuttavia insulinotrooppisia komplekseja, koostumuksia ja menetelmiä
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
PL1751184T3 (pl) Białka fuzyjne FGF-21
CY1106971T1 (el) Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης
Bolli et al. Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
EP1145717A3 (de) Synergistische Wirkung von einem Sulfonylharnstoff und/oder einem nicht Sulfonylharnstoff K-ATP Kanalblocker und einem cAMP-Phosphodiestrerase Typ 3 Inhibitor
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2006096565A3 (en) Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
BR9106225A (pt) Componente betume/polimero que permite obter composicoes de betume/polimero de suscetibilidade termica muito baixa utilizaveis para a realizacao de revestimentos
NO20015932L (no) Fremgangsmåte til å behandle diabetes
WO2005070444A8 (en) Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
TR200000134T2 (tr) Tiazolidinedion, ensülin salgılatıcısı ve biguanid ile diabetin (şeker hastalığının) tedavisi.
WO2005002612A8 (en) Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
Scelles et al. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.
BR0103209A (pt) Uso de ácido fitânico para o tratamento de diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties